Skip to Content
May. 8, 2017, 10:27 AM
The Vanderbilt-Ingram Cancer Center (VICC) has been invited to participate in The V Foundation 2017 Pediatric Cancer Research–Immunology or Immunotherapy Award. The Pediatric Cancer Research–Immunology or Immunotherapy Award is a three-year grant of $200,000 per year.
VICC may nominate one candidate for this award. Translational projects should move a novel strategy from the laboratory into a human clinical trial or use specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than five years. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial. A maximum of 10 percent indirect costs (within the award amount) are supported in the award. NIH salary caps are observed.
Applicant eligibility: By the due date of the application, applicants who will lead this research team must have all of the following:
Anyone interested in being considered as Vanderbilt’s nominee must submit the following (in PDF format) to LSO@vanderbilt.edu by 5 p.m. Monday, May 15.
Submissions should reference the program name in the subject line of the email.
Once received, all proposals will be forwarded to an internal review committee that will choose the final nominee. The chosen nominee will submit a full proposal to the foundation by the June 2 deadline.
If you have any questions about the foundation or its interests and priorities, please contact Megan Smallwood in the Office of Research or Adele White in the Corporate and Foundation Relations Office.
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: